Accelerating the Development of New Alpha Therapies for Cancer Treatment

点击翻译按钮获取中文摘要

The overall aim of the present proposal is to take full advantage of the treatment potential of a new cancer therapy. This involves novel radiopharmaceuticals that incorporate alpha-emitting radioactive isotopes for cancer-specific targeted alpha therapy (TAT), which is expected to revolutionize cancer care. The development and implementation of this new treatment is, however, hindered and delayed due to the cumbersome detection of alpha emitters during the TAT pharmaceutical development. We will change this by developing a new advanced alpha sensor for the pharmaceutical industry. The sensor will facilitate and greatly simplify monitoring, benchmarking, and quality control of the TAT radiopharmaceutical. The sensor will be principally based on UK detector technology which has been developed under an STFC-funded research programme for nuclear structure and nuclear astrophysics experiments at TRIUMF, Canada.